Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

This study is examining the use of a drug called ublituximab (brand name Briumvi) in adults who have been newly diagnosed with multiple sclerosis (MS) and are starting treatment early in their disease course. Ublituximab is a B-cell depleting infusion therapy already approved for MS, and this study will follow participants over time to understand outcomes in early MS. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with MS within the past 5 years according to 2024 diagnostic criteria - Your EDSS disability score is below 2.5 (meaning minimal disability) - You have fewer than 10 demyelinating brain lesions on MRI - You are already planning to start ublituximab for relapsing MS **You may NOT be eligible if...** - You have previously received powerful immune-depleting treatments such as Mavenclad, Lemtrada, cyclophosphamide, or stem cell transplant - You have previously received other B-cell depleting drugs such as Ocrelizumab, Rituximab, Ofatumumab, or Inebilizumab - You have had major surgery in the past 6 months - You are currently in another clinical trial - Your MS diagnosis is unclear or poorly documented Talk to your doctor to see if this trial is right for you.